Lifeward (LFWD)
NASDAQ:LFWD
Want to see LFWD full AI Analyst Report?
Top Page
Lifeward
(NASDAQ:LFWD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$7.00
▲(3.09% Upside)
Action:Reiterated
Date:05/19/26
LFWD scores low primarily due to persistently loss-making financials and multi-year cash burn with a weakened equity position. Technicals also remain bearish with price below major moving averages and negative MACD. The earnings call provides partial support via improved liquidity and reduced cash burn, but near-term revenue and margin headwinds keep overall risk elevated.
Positive Factors
Stronger liquidity via financing
The incremental $9.2M net cash infusion materially extends runway versus year-end levels and reduces immediate refinancing pressure. With higher liquidity the company can integrate acquisitions, support backlog fulfillment, and fund product commercialization, lowering short-term funding reliance while management executes toward profitability.
Negative Factors
Persistent negative cash flow
Sustained negative operating and free cash flows demonstrate the company is not self-funding. Ongoing multi‑year cash burn increases dependence on external financing, raises dilution risk, constrains investment in commercial scale‑up, and limits flexibility to absorb operational shocks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger liquidity via financing
The incremental $9.2M net cash infusion materially extends runway versus year-end levels and reduces immediate refinancing pressure. With higher liquidity the company can integrate acquisitions, support backlog fulfillment, and fund product commercialization, lowering short-term funding reliance while management executes toward profitability.
Read all positive factors
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.84M
Dividend YieldN/A
Average Volume (3M)316.99K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-17.67%
EPS Growth46.19%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-19.66
Shares Outstanding2,814,409
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue0.39
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$10.00Price Target Upside47.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.47
Revenue Forecast (FY)$30.11M
Lifeward Business Overview & Revenue Model
Company Description
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand up...
How the Company Makes Money
Lifeward generates revenue primarily by selling its ReWalk exoskeleton systems and associated accessories to customers in clinical/rehabilitation and personal-use settings, with revenue recognized based on product sales and deliveries. The company...
Lifeward Earnings Call Summary
Earnings Call Date:May 15, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.Positive Updates
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Negative Updates
Quarterly Revenue Decline
Total revenue for Q1 2026 was $3.9 million vs. $5.0 million in Q1 2025, a decline of approximately 22%, primarily due to reduced AlterG shipments from temporary supply chain and working capital constraints.
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Read all positive updates
Company Guidance
Management did not raise formal 2026 guidance but reiterated they expect full‑year revenue to be similar to 2025, with the Q1 shortfall ($3.9M vs. $5.0M in Q1‑2025) to be largely made up across Q2–Q3 as AlterG backlog ships (potentially resolved by Q3); they highlighted ReWalk revenue up 11% YoY to $1.6M, gross margin down to 34.2% from 42.2% (~800 bps, 75–85% due to FX and tariffs and the rest from lower absorption), total operating expenses of $11.7M (including a ~$4.9M one‑time noncash R&D charge), adjusted Opex down 12% to $5.9M (from $6.8M), GAAP operating loss of $10.3M and unchanged adjusted operating loss of $4.6M, cash used in operations down 33% to $3.7M, and liquidity improved to $11.4M unrestricted cash (vs. $2.2M at YE‑2025) after a $10M convertible financing and ~ $6.5M cash from the Oratech acquisition, positioning the company for operational stabilization and a clearer path to profitability into late 2026/2027.Lifeward Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.92M | 22.03M | 25.66M | 13.85M | 5.51M | 5.97M |
| Gross Profit | 7.65M | 8.43M | 8.22M | 4.45M | 1.91M | 2.90M |
| EBITDA | -22.13M | -16.56M | -24.93M | -21.77M | -18.90M | -12.39M |
| Net Income | -25.87M | -19.91M | -28.94M | -22.13M | -19.57M | -12.74M |
Balance Sheet | ||||||
| Total Assets | 33.42M | 22.90M | 30.49M | 63.19M | 74.24M | 94.75M |
| Cash, Cash Equivalents and Short-Term Investments | 11.42M | 2.17M | 6.94M | 28.08M | 67.90M | 88.34M |
| Total Debt | 8.81M | 1.58M | 880.00K | 1.90M | 897.00K | 1.06M |
| Total Liabilities | 27.13M | 14.49M | 11.64M | 16.68M | 6.07M | 5.37M |
| Stockholders Equity | 6.29M | 8.41M | 18.85M | 46.51M | 68.17M | 89.38M |
Cash Flow | ||||||
| Free Cash Flow | -15.02M | -16.83M | -21.72M | -20.75M | -17.92M | -11.52M |
| Operating Cash Flow | -15.01M | -16.83M | -21.72M | -20.67M | -17.89M | -11.47M |
| Investing Cash Flow | 6.49M | -16.00K | 0.00 | -18.15M | -25.00K | -47.00K |
| Financing Cash Flow | 14.15M | 12.20M | 0.00 | -992.00K | -2.50M | 79.51M |
Lifeward Technical Analysis
Positive
6.79
Price Trends
6.82
Positive
6.89
Positive
7.30
Negative
Market Momentum
-0.09
Positive
55.96
Neutral
54.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Positive. The current price of 6.79 is below the 20-day moving average (MA) of 6.81, below the 50-day MA of 6.82, and below the 200-day MA of 7.30, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 55.96 is Neutral, neither overbought nor oversold. The STOCH value of 54.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 43 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifeward Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $18.26M | -0.11 | -70.27% | ― | -9.46% | 18.03% | |
46 Neutral | $5.09M | -0.21 | -279.58% | ― | 129.04% | 74.30% | |
45 Neutral | $45.75M | ― | -9999.00% | ― | -95.74% | -118.94% | |
44 Neutral | $19.84M | -0.25 | -127.95% | ― | -17.67% | 46.19% | |
43 Neutral | $7.69M | -1.19 | -84.30% | ― | -23.81% | 32.96% | |
42 Neutral | $62.78K | >-0.01 | ― | ― | ― | ― |
* Healthcare Sector Average
LFWD
Lifeward
6.98
-7.90
-53.09%
BMRA
Biomerica
2.47
-0.71
-22.33%
CODX
Co-Diagnostics
9.11
1.64
21.95%
XAIR
Beyond Air
0.44
-3.36
-88.50%
PAVM
PAVmed
6.14
-13.56
-68.83%
DHAI
DIH Holdings US, Inc Class A
0.03
-6.37
-99.53%
Lifeward Corporate Events
Business Operations and StrategyExecutive/Board Changes
Lifeward Names Keith D. Rose as Chief Medical Officer
Positive
May 19, 2026
On May 18, 2026, Lifeward Ltd. announced that it had appointed Keith D. Rose, M.D. as Chief Medical Officer, effective May 1, 2026, reinforcing its leadership bench in neurosciences-focused medical affairs. Dr. Rose brings extensive experience fro...
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Lifeward Restores Nasdaq Compliance With Audit Committee Changes
Positive
Mar 31, 2026
Lifeward Ltd. had previously fallen out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned from its board and audit committee, leaving the committee with fewer than the required three members. On March 30, 2026...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Lifeward Completes Oratech Acquisition and Secures Private Financing
Positive
Mar 25, 2026
On March 25, 2026, Lifeward completed its previously announced acquisition of Oratech Pharma from Oramed, issuing 2,256,476 ordinary shares and pre-funded warrants, along with additional transaction warrants and a revenue-sharing arrangement tied ...
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Lifeward Faces Nasdaq Audit Committee Compliance Challenge
Negative
Mar 20, 2026
On March 17, 2026, Lifeward Ltd. disclosed it had received a notice from Nasdaq’s Listing Qualifications Department that the company no longer complies with Listing Rule 5605(c)(2)(A), after director Hadar Levy’s resignation reduced it...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Lifeward Shareholders Approve Oratech Deal and Governance Changes
Positive
Mar 13, 2026
Lifeward Ltd. reported that 7,252,783 ordinary shares, representing about 39.7% of its outstanding shares as of January 20, 2026, were present or voted at its March 12, 2026 extraordinary general meeting, establishing quorum and enabling sharehold...
Delistings and Listing ChangesRegulatory Filings and Compliance
Lifeward Regains Compliance With Nasdaq Minimum Bid Rule
Positive
Mar 11, 2026
On March 10, 2026, Lifeward Ltd. announced it had regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum closing bid price of at least $1.00 for 10 consecutive business days, from February 24 to Marc...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Lifeward Executes Reverse Share Split to Maintain Listing
Neutral
Mar 2, 2026
On February 24, 2026, Lifeward Ltd. implemented a 1-for-12 reverse share split of its ordinary shares following shareholder approval at an extraordinary general meeting held on January 6, 2026 and subsequent board finance committee decisions in la...
Executive/Board Changes
Lifeward Announces Routine Board Change with Director Resignation
Neutral
Feb 27, 2026
On February 24, 2026, Lifeward Ltd. announced that Class I director Hadar Levy resigned from the board, effective the same day, in a move the company said was not related to any disagreement over operations, policies or practices. The board expres...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.